Published today in the European Heart Journal ahead of its Saturday presentation: the first ESC guideline that treats cardiovascular disease and chronic kidney disease as one condition, endorsed by the European Renal Association and chaired by Kevin Damman (UMC Groningen) with William Herrington (Oxford); Jozine ter Maaten (UMCG) co-ordinated. Class I: every patient with CVD is tested for CKD with creatinine-based eGFR and a spot morning urine albumin-to-creatinine ratio, classified by GFR and albuminuria, confirmed over three months. SGLT2 inhibitors across CKD stages and in heart failure regardless of LVEF, early RAS inhibition, finerenone, GLP-1 receptor agonists in diabetes, statins, DOACs over VKA down to an eGFR of 15. The STAMP framework: Screen, Triage, Address CKD risk, Modify CVD management, Plan services.
